Moderna said it is in discussions with the FDA to provide post-marketing data on its COVID-19 vaccines, aiming to restore broader use after FDA leaders narrowed the label last year. The company’s update reflects how post-marketing evidence requirements are shaping mRNA vaccine access, even after product rollouts. Moderna’s effort also coincides with its financial recovery from international sales, and sets up another policy and evidence negotiation between the sponsor and regulators.